Supportive Care for Patients with Lymphoma Undergoing CAR-T-cell Therapy: the Advanced Practice Provider's Perspective

Purpose of Review The purpose of our paper is to describe the all-encompassing supportive care for patients with relapsed or refractory lymphoma undergoing cellular therapy, with a focus on the advanced practice provider's (APPs) perspective. Recent Findings Chimeric antigen receptor-T (CAR-T) cell therapy has become more available for treating relapsed or refractory B-cell hematologic malignancies, requiring proficient and adequate treatment of side effects, complications, and infections that may occur during therapy. APPs often meet these patients during the initial referral and help to support them through the CAR-T cell therapy process. Summary As APPs acquire a complete understanding and comprehensive knowledge of how to treat, support, and guide patients with B-cell malignancies through CAR-T cell therapy, they play a pivotal role in these patients throughout their treatment. Standardization of supportive care is paramount.

Automated summary

This paper aims to describe the comprehensive supportive care for patients with relapsed or refractory lymphoma undergoing cellular therapy, focusing on the perspective of advanced practice providers (APPs). Recent findings indicate that CAR-T cell therapy is increasingly used for treating relapsed or refractory B-cell hematologic malignancies. APPs play a pivotal role in supporting these patients throughout their treatment.